Natick
NATICK, Massachusetts and PARIS, May 23, 2011 -
- 12-Month Clinical Data Demonstrate Low Adverse Event Rates for Boston
Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) today announced
12-month results from its PLATINUM Small Vessel study, demonstrating
excellent safety and effectiveness outcomes for the 2.25 mm PROMUS
Element(TM) Everolimus-Eluting Platinum Chromium Stent System in treating
small vessel coronary disease.
NATICK, Massachusetts, May 9, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced the
U.S.
NATICK, Massachusetts, May 6, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced the
launch and first implants of its ENERGEN(TM) and PUNCTUA(TM) cardiac
resynchronization therapy defibrillators (CRT-Ds) and implantable
cardioverter defibrillators (ICDs) in Europe and other international markets.
Reduction of Geographic Miss and Bail-out Stenting Observed With Highly Visible PROMUS Element Stent
NATICK, Massachusetts and NEW ORLEANS, April 5, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced
12-month results from the pivotal PLATINUM Workhorse trial comparing the
safety and effectiveness of the PROMUS Element(TM) Everolimus-Eluting
Platinum Chromium (PtCr) Coronary Stent System to the PROMUS(R)
Everolimus-Eluting Coronary Stent System.
NATICK, Massachusetts, March 7, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced it
has received CE Mark for its OMEGA(TM) Platinum Chromium Bare-Metal Coronary
Stent System, the Company's third-generation coronary stenting technology.
More News
- Boston Scientific Announces CE Mark Approval and First Implants for New Devices to Treat Heart Failure and Sudden Cardiac Death
- Boston Scientific Announces Australia and New Zealand Approval for its LATITUDE(R) Patient Management System
- Company's Fully Covered Metal Stent Now Approved for Use in Treating Benign Biliary Strictures
- Latest Innovation in Plastic Biliary Stent Technology Includes Features for Enhanced Deliverability, Efficiency and Procedural Control
- MADIT II Eight-Year Outcomes Analysis Shows That One Life is Saved for Every Eight Patients Who Receive an ICD
- Nine-month Results From PLATINUM Clinical Program Presented at TCT
- PROMUS(R) Element(TM) Stent Approved for Use in Diabetic and Heart Attack Patients in CE Mark Countries
- FDA Approval is Based on Results From the Company's Landmark MADIT-CRT Trial
- EVOLVE Trial to Evaluate Company's Fourth-Generation SYNERGY(TM) Drug-Eluting Coronary Stent
- Company Expands Market-leading Family of Neurovascular Stents
- Boston Scientific Announces First Patient Enrollment in MultiSENSE Clinical Trial
- MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
- CE Mark Approval Includes Specific Indication for Treatment of Diabetic Patients
- Randomized Study of Nearly 3,000 Patients to Evaluate Company's Third-Generation Drug-Eluting Stent Technology
- Approval Includes Specific Indication for Treatment of Diabetic Patients
- Company's CRT-Ds Recommended for Asymptomatic and Mild Heart Failure Patients
- PERSEUS Trial Results Demonstrate Positive Safety and Efficacy Outcomes for Boston Scientific's Novel Platinum Chromium TAXUS(R) Element(TM) Stent System
- Boston Scientific Announces Enrollment of First Patient in Benign Stricture Study of WallFlex(R) Biliary RX Stent
- Boston Scientific Announces Completion of Enrollment in Aneurysm Coiling Clinical Trial
- Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets
- MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
